Pharmaxis says majority of patients in fibrosis trial see significant improvement

–News Direct–

Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips speaks with Proactive after releasing data from a final interim analysis of 10 patients who have completed six months treatment with its drug PXS-5505 in an open label phase 2 clinical trial in patients with the bone marrow cancer myelofibrosis.

The data points to an excellent safety profile and promising signs of clinical activity, with 60% of patients who reached the six-month mark showing improved bone marrow fibrosis scores.

PXS-5505 continues to show not only an excellent safety profile but also promising clinical activity, MD Anderson Cancer Center, Department of Leukemia assistant professor Dr Lucia Masarova said.

The effect on bone marrow fibrosis is particularly exciting for a disease like myelofibrosis, where despite numerous years of research, we do not have any effective anti-fibrotic drugs.

It is encouraging to see that majority of 10 patients who completed 24 weeks of therapy also had improvements of symptoms and more importantly, stable or improved blood counts; including in those patients with severe thrombocytopenia.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/pharmaxis-says-majority-of-patients-in-fibrosis-trial-see-significant-improvement-222912765

Pharmaxis Ltd

COMTEX_436787901/2655/2023-07-13T11:31:46